GBIO Quote, Financials, Valuation and Earnings

Grace Therapeutics has a net margin of -510.55% compared to Generation Bio's net margin of --. Generation Bio's return on equity of -102.68% beat Grace Therapeutics's return on equity of --.

Generation Bio has a consensus price target of $6.75, signalling upside risk potential of 1504.85%. On the other hand Grace Therapeutics has an analysts' consensus of $11.86 which suggests that it could grow by 398.32%. Given that Generation Bio has higher upside potential than Grace Therapeutics, analysts believe Generation Bio is more attractive than Grace Therapeutics.

Generation Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Grace Therapeutics has a beta of 1.327, suggesting its more volatile than the S&P 500 by 32.655%.

Generation Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grace Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio pays -- of its earnings as a dividend. Grace Therapeutics pays out -- of its earnings as a dividend.

Generation Bio quarterly revenues are $4.2M, which are larger than Grace Therapeutics quarterly revenues of --. Generation Bio's net income of -$21.4M is lower than Grace Therapeutics's net income of -$4.2M. Notably, Generation Bio's price-to-earnings ratio is -- while Grace Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio is 1.41x versus -- for Grace Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -510.55% compared to Generation Bio's net margin of -711.67%. Generation Bio's return on equity of -102.68% beat IGC Pharma's return on equity of -116.24%.

Generation Bio has a consensus price target of $6.75, signalling upside risk potential of 1504.85%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1134.86%. Given that Generation Bio has higher upside potential than IGC Pharma, analysts believe Generation Bio is more attractive than IGC Pharma.

Generation Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.948%.

Generation Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Generation Bio quarterly revenues are $4.2M, which are larger than IGC Pharma quarterly revenues of $257K. Generation Bio's net income of -$21.4M is lower than IGC Pharma's net income of -$1.8M. Notably, Generation Bio's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio is 1.41x versus 18.45x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -510.55% compared to Generation Bio's net margin of -49.65%. Generation Bio's return on equity of -102.68% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Generation Bio has a consensus price target of $6.75, signalling upside risk potential of 1504.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.07%. Given that Generation Bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe Generation Bio is more attractive than NovaBay Pharmaceuticals.

Generation Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Generation Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Generation Bio quarterly revenues are $4.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Generation Bio's net income of -$21.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Generation Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio is 1.41x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -510.55% compared to Generation Bio's net margin of 35.65%. Generation Bio's return on equity of -102.68% beat Protalix BioTherapeutics's return on equity of 8.75%.

Generation Bio has a consensus price target of $6.75, signalling upside risk potential of 1504.85%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 393.2%. Given that Generation Bio has higher upside potential than Protalix BioTherapeutics, analysts believe Generation Bio is more attractive than Protalix BioTherapeutics.

Generation Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Generation Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Generation Bio quarterly revenues are $4.2M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Generation Bio's net income of -$21.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Generation Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 98.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio is 1.41x versus 4.57x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.